Compare Herbalife Nutrition Ltd (HLF) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Herbalife Nutrition Ltd vs Recursion Pharmaceuticals Inc — how do they compare? Herbalife Nutrition Ltd trades at $11.75 (market cap $1.23B), while Recursion Pharmaceuticals Inc trades at $3.3 (market cap $1.81B). The key difference: Recursion Pharmaceuticals Inc is the larger of the two by market cap, and Herbalife Nutrition Ltd is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| HLF | RXRX | |
|---|---|---|
Market Cap | $1.23B | $1.81B |
Sector | Consumer Staples | Health |
52-Week High | $19.96 | $6.79 |
52-Week Low | $7.75 | $2.84 |
Enterprise Value | $3.06B | $1.33B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HLF trades at $11.71, up 1.65% on the day, with a bearish technical signal from moving averages. The company shows mixed earnings, missing Q2 2026 EPS estimates but achieving four consecutive quarters of sales growth. Valuation ratios appear attractive with a P/E of 7.53 and P/S of 0.24, though negative shareholder equity and high debt levels present financial risks. Recent news includes a planned CFO transition and inclusion in TIME's America's Best Companies 2026 list.
The outlook for HLF balances low valuation against operational and financial challenges. Investment opportunity lies in potential margin improvement and debt reduction, but risks include earnings volatility, high leverage, and competitive pressures in the nutrition space. Analyst sentiment is cautiously optimistic with a majority buy rating.
RXRX trades at $3.295, up 0.15% on the day, with a bullish technical signal from moving averages but mixed oscillators. The company reported a Q2 2026 earnings miss with revenue declining year-over-year, while maintaining a strong cash position from financing activities. Recent news highlights participation in investor conferences and partnership advancements with Genentech.
Outlook remains speculative with high revenue growth potential from AI-driven drug discovery partnerships, but significant risks persist due to deep losses and negative margins. Analyst sentiment is mixed with a 40% buy rating, emphasizing the stock's high-risk, high-reward profile dependent on future clinical and commercial milestones.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Herbalife Nutrition Ltd
Herbalife Nutrition Ltd is an international nutrition company.
Read more on HLF →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
